Tilray Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 2 sell ratings and 10 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Tilray stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View analyst ratings for Tilray or view top-rated stocks.

Wall Street analysts have given Tilray a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tilray wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Tilray is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Tilray.

Tilray Inc (NASDAQ:TLRY) posted its quarterly earnings results on Monday, November, 9th. The company reported ($0.02) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.19. The company earned $51.41 million during the quarter, compared to analysts' expectations of $54.91 million. Tilray had a negative trailing twelve-month return on equity of 92.70% and a negative net margin of 242.60%. Tilray's revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.36) EPS.
View Tilray's earnings history.

Tilray's stock was trading at $7.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TLRY stock has increased by 205.1% and is now trading at $21.63.
View which stocks have been most impacted by COVID-19.

12 brokerages have issued 1 year target prices for Tilray's stock. Their forecasts range from $4.75 to $32.00. On average, they expect Tilray's stock price to reach $18.31 in the next year. This suggests that the stock has a possible downside of 15.4%.
View analysts' price targets for Tilray or view top-rated stocks among Wall Street analysts.

32 employees have rated Tilray CEO Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among Tilray's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Tilray include Canopy Growth (CGC), STADA Arzneimittel Aktiengesellschaft (STDAF), Aphria (APHA), Cronos Group (CRON), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Sundial Growers (SNDL), HEXO (HEXO), ChromaDex (CDXC), Canopy Rivers (RIV), Charlie's (CHUC), MediWound (MDWD), Natural Alternatives International (NAII), Nutra Pharma (NPHC) and Happiness Biotech Group (HAPP).
View all of TLRY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Tilray's stock is owned by a number of retail and institutional investors. Top institutional investors include ETF Managers Group LLC (5.22%), Founders Fund V Management LLC (0.45%), Magnetar Financial LLC (0.31%), Graham Capital Management L.P. (0.14%), Princeton Global Asset Management LLC (0.12%) and Raymond James Financial Services Advisors Inc. (0.11%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends for Tilray.

TLRY stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Engineers Gate Manager LP, and Stelac Advisory Services LLC. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, Maryscott Greenwood, and Michael Auerbach.
View insider buying and selling activity for Tilray or view top insider-selling stocks.

TLRY stock was purchased by a variety of institutional investors in the last quarter, including Founders Fund V Management LLC, ETF Managers Group LLC, Magnetar Financial LLC, Graham Capital Management L.P., Raymond James Financial Services Advisors Inc., Seven Eight Capital LP, Nuveen Asset Management LLC, and Credit Suisse AG.
View insider buying and selling activity for Tilray or or view top insider-buying stocks.

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TLRY stock can currently be purchased for approximately $21.63.

Tilray has a market capitalization of $3.72 billion and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

Tilray employs 1,646 workers across the globe.

The official website for Tilray is www.tilray.com.

Tilray is headquartered at 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.